EYPT Stock Analysis: Buy, Sell, or Hold?
EYPT - EyePoint Pharmaceuticals, Inc. Common Stock
$13.98
0.79 (5.95%)
▲
5d:
+1.97%
30d:
+11.57%
90d:
+7.37%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 6.0/10
Get Alerted When EYPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EYPT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: EYPT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: EYPT is currently trading at $13.98, which is considered extended relative to its 30-day fair value range of $12.29 to $13.93.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $13.01, while resistance sits at $15.92. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: EYPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.00 (+186.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $13.01, while resistance sits at $15.92. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: EYPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.00 (+186.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.29 -
$13.93
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 186.1% below Wall St target ($40.00)
Trading Range Analysis
30-Day Trading Range
$12.29 -
$13.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.01
Resistance Level
$15.92
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.95
Wall Street Target
$40.00
(+186.1%)
Revenue Growth (YoY)
161.7%
Share & Embed Analysis
Last updated: July 02, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EYPT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ramiro Ribeiro
SELL
2437 shares
2026-04-17
Jay S Duker
BUY
1500 shares
2026-03-16
Ramiro Ribeiro
SELL
42544 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
